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Treatments for neonatal hypoxic-ischemic encephalopathy (HIE) have been limited.The aim
of this paper is to offer translational research guidance on stem cell therapy for neonatal
HIE by examining clinically relevant animal models, practical stem cell sources, safety and
efficacy of endpoint assays, as well as a general understanding of modes of action of
this cellular therapy. In order to do so, we discuss the clinical manifestations of HIE, high-
lighting its overlapping pathologies with stroke and providing insights on the potential of
cell therapy currently investigated in stroke, for HIE. To this end, we draw guidance from
recommendations outlined in stem cell therapeutics as an emerging paradigm for stroke
or STEPS, which have been recently modified to Baby STEPS to cater for the “neonatal”
symptoms of HIE. These guidelines recognized that neonatal HIE exhibit distinct disease
symptoms from adult stroke in need of an innovative translational approach that facilitates
the entry of cell therapy in the clinic. Finally, new information about recent clinical trials and
insights into combination therapy are provided with the vision that stem cell therapy may
benefit from available treatments, such as hypothermia, already being tested in children
diagnosed with HIE.
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CLINICAL MANIFESTATIONS OF NEONATAL
HYPOXIC-ISCHEMIC BRAIN INJURY
Hypoxic-ischemic encephalopathy (HIE), cerebral palsy (CP),
and periventricular leukomalacia (PVL) are mainly triggered
by neonatal hypoxic-ischemic brain injury. Neurodevelopmen-
tal deficits such as learning disabilities, mental retardation, and
hearing and visual impairments accompany children diagnosed
with hypoxic-ischemic brain injury. Brain expression of systemic
asphyxia characterizes HIE (1). Perinatal asphyxia and resulting
hypoxic-ischemic encephalopathy (HIE) occur in 1–3 per 1000
births in the United States (2). Worldwide, 10–60% of infants who
develop HIE will die and at least 25% of the survivors will have
long-term neurodevelopmental sequelae (2). Hypoxic-ischemic
encephalopathy is the primary cause of 15–28% of cerebral palsy
among children (2). Throughout the paper, the terms HIE and the
alternative term neonatal encephalopathy (NE) (3, 4) are synony-
mous. These two terminologies have been a topic of much debate
(5, 6). Even with an intense effort by researchers and clinicians to
employ precise diagnostic methods, encephalopathy has not been
identified in premature infants as compared to full term infants
(7–9). HIE brings a relatively high 50% mortality rate in newborns
(10), and a small portion of those survivors, 25% display CP symp-
toms permanently (11,12). Ischemic perinatal stroke is responsible
for 30% of children with CP (13). A cerebral white matter injury,
known as PVL, is detected in 50% of neonates with exceedingly low
Abbreviations: CP, cerebral palsy; HI, hypoxic-ischemia; HIE, hypoxic-ischemic
encephalopathy; MSCs, mesenchymal stem cells; NE, neonatal encephalopathy;
PVL, periventricular leukomalacia; STEPS, stem cell therapeutics as an emerging
paradigm for stroke.
birth weights with 90% of survivors displaying CP symptoms (14);
however, studies using ultrasonography report findings of the inci-
dence of PVL to be lower than 50% (15–17). As a result of the very
similar pathophysiological symptoms between neonatal hypoxic-
ischemic brain injury and adult stroke, innovative treatments such
as cell-based therapies, which are currently being tested in stroke,
may prove to be successful in neonatal hypoxic-ischemic brain
injury. Having a grasp of the neurochemical cascade of events is
a holy grail for commencing treatment intervention in neonates
(18). To this end, therapeutic benefits may be achieved by abrogat-
ing the“secondary energy failure”or“excite-oxidative cascade”(18,
19). This is characterized by amplified excitation of NMDA recep-
tors combined with peculiar oxidative stress due to mitochondrial
dysfunction, altogether depleting energy from the brain seen in
infants with hypoxic-ischemic injury (18). Currently, hypother-
mia is used to treat HIE (20–22) and has demonstrated to be very
effective in newborns with a gestational age of ≥36 weeks (22,
23) diagnosed with moderate to severe HIE (21, 22), but neu-
rodevelopmental deficits persist in 40–50% of patients even after
hypothermia (22). A treatment that combines both hypothermia
and cell transplantation may prove to be more effective and benefit
neonates with moderate to severe HIE (Figure 1).
KEY PRECLINICAL GATING ITEMS FOR STEM CELL THERAPY
FOR HIE
Academicians, industry partners, and regulators, which include
both the National Institutes of Health (NIH) and the U.S. Food and
Drug Administration (FDA), have jointly created Stem cell Ther-
apeutics as an Emerging Paradigm for Stroke (STEPS). Together,
they have provided guidelines to increase the successful outcome
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FIGURE 1 | Multiple intended combination therapies are shown for
three different groups: acute (0–48h after birth), subacute (6–72h
after birth), or chronic (>72h after birth). The joint effort of both cell
transplantation therapy and neuroprotective therapies, such as
hypothermia, erythropoietin (EPO), and helium are used for treating
neonates with HIE. When treating the neonate in the acute or subacute
phase, the treatment is referred to as neuroprotection. On the other hand,
treatments aimed at the chronic stage are referred to as neurorestoration.
EPO or helium is used to treat the subject during the acute phase, while
hypothermia and stem cell therapy is used to treat the subacute stage via
intravascular routes. When treating the chronic stage, stem cell therapy is
used via intracerebral route, which stimulates the neurorestorative
mechanisms. The combination of these therapies may prove to be
effective in neonates suffering from HIE.
of cell therapy in stroke patients (24–31). The need for the estab-
lishment of a Baby STEPS consortium is necessary for younger
patients (32). This would allow a safe and effective translation of
cell therapy in neonatal hypoxic-ischemic brain injury. Below, we
identify critical gating criteria in conducting translational stud-
ies in order to aid and advance the formation of Baby STEPS
guidelines.
CLINICALLY RELEVANT MODELS OF HIE
The animal species and strain should be specially considered
in HIE modeling. Rodent models such as Vannucci’s model of
neonatal hypoxic-ischemic brain injury parallel many pathological
events that humans endure during neonate HIE (33). Researchers
found that in 7-day-old postnatal rats, which undertook ligation
of unilateral carotid artery as well as systemic hypoxia, suffered
widespread cell death to cerebral cortex, subcortical and periven-
tricular white matter, striatum, and hippocampus ipsilateral to the
ligated artery (34). Rats are not the only species used to create the
Vannucci model, but mice have also been used (35) with varying
pathological outcomes dependent on the mouse strain (36–39).
Another equally important variable that should be controlled
in the experimental HIE is the age of the animals. Younger animals
have shown to be impervious against hypoxia. A 1–2-day-old post-
natal rat needs to be exposed to more severe hypoxia as compared
to its 7-day-old counterpart in order to attain efficacious HIE
symptoms (40). Another important fact to note is that younger
animals experience worse white matter injury than older rats (35).
Therefore in HIE modeling, age is a critical factor and is fur-
ther verified by a focal subcortical cell loss paired with a surge
in proliferating oligodendrocyte progenitor cells following HIE in
young neonates, but rather modest in older models (41–45). Age-
related changes following HIE need to become standardized in
order to better evaluate the therapeutic benefits of experimental
treatments.
Gender should also be taken into consideration for models,
in that HIE-induced female neonates displayed a much smaller
infarct volume and improved sensorimotor task than their male
counterparts after perinatal hypoxic-ischemic brain injury and
treatment with erythropoietin (46). A possible explanation behind
the differences between female and male neonatal infarct sizes and
improved neurological behavior has become increasingly clear. It
is known that gender differences in injury to the brain are not
merely a result of hormonal influence (47), but the properties of
individual cells (48). For instance, male and female cells display
differential gene expression even when no hormonal influences
are apparent (49), and brain cells show phenotypic differences
that are gender dependent but independent of gonadal phenotype
(50). Moreover, gender modulates responsiveness to recombinant
erythroprotein (Epo) (51). Additionally, Epo receptor (EpoR) alle-
les, EpoRA1, and EpoRA10, have displayed a significantly higher
frequency in females when compared to males (52). Epo adminis-
tration is known to produce significant long-term neuroprotective
benefit on the developing brain (46). This suggests that Epo has a
gender preference with neonatal benefit in females, whose mech-
anisms must be further investigated. Together with other studies
demonstrating that gender similarly affects injury models (53, 54),
these studies suggest that gender should be carefully considered in
experimental HIE.
The approximation of the clinical pathology of HIE is a crucial
goal in standardizing the animal models because a model that bet-
ter mimics a human condition would allow for better evaluations
of possible treatments in human patients. Rats along with many
other species, which include non-human primate, sheep, lamb,
puppy, piglet, and rabbit, have been employed as models to closely
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resemble some HIE pathological aspects in humans (33, 55–60).
Unfortunately, because of the expense in using large animal mod-
els, it has deterred research with these clinically relevant models.
The piglet model is a good model for research regarding treatment
plans for neonates, as it closely resembles the weight and size of
a newborn infant. This piglet model also reveals new treatment
variables, in that phosphorylated metabolites are temperature-
sensitive and that the more severe the energy depletion the worse
the secondary energy failure, exacerbating neuronal death (61,
62). These findings suggest the need to control temperature and
maintain brain injury in experimental models using therapeutic
strategies.
CLINICALLY RELEVANT EXPERIMENTAL PARADIGMS
Lab-to-clinic translatable functional tests need to be developed
to better assess the pathological improvements of experimental
interventions for short and long-term outcomes that are species
specific and mimic the human condition. Despite efforts of inves-
tigators to control many variables in experimental HIE models,
characterizing the phenotype of encephalopathy in neonates has
proven to be elusive. As opposed to adults, neonatal encephalopa-
thy is prevented from implementation of timely interventions as
there is a scarcity in studies determining the optimal supra-acute
to chronic therapeutic window in laboratory models, thus pre-
senting a major barrier to translating experimental treatments to
clinical applications. Acknowledging this research gap is pivotal
when designing therapeutic intervention studies for future clinical
applications in neonates. In order to create well-designed transla-
tional studies, it is critical to optimize the dosage, delivery route,
and timing of stem cell transplantation within applicable clinical
parameters. Treating the laboratory as the clinical setting for cell
therapy in HIE will enhance the translational potential of the stem
cell product. In order to prevent any potential microembolism,
the minimum therapeutic cell dosage must be determined. Find-
ing minimally invasive procedures for cell delivery could prevent
exacerbation of the already injured brain. For timing of cell deliv-
ery, consideration should be given to the neuroprotective phase
(< 1 day of injury) and the neurorestorative phase (> 1 day after
injury) (63, 64). While most transplant studies have examined
a single bolus injection of stem cells, we recognize that HIE is
a disorder that involves progressive neuronal cell loss even days
after HI. As a result, multiple treatments of stem cells and adjunct
neuroprotective therapies are more likely to have not only neu-
roprotective but also neurorestorative effects. This would provide
a continual targeted regime to prevent cell death in the hopes to
improve neurodevelopmental outcome. For example, two MSC
injections at 3 and 10 days after neonatal hypoxia-ischemia (HI)
markedly improved sensorimotor function 4 weeks after the insult
(65). This MSC-3+ 10 treatment was more powerful in improv-
ing functional outcome and in reducing gray and white matter loss
than a single MSC injection at 3 days after HI (65).
WELL-DEFINED PHENOTYPIC MARKERS OF DONOR STEM CELLS
A detailed description of the distinguishable phenotypic features
of stem cells is an integral component of understanding the biol-
ogy and potential of stem cells (66–74). To determine the safety
and effectiveness of stem cells that are to be transplanted in HIE,
it is important to know their identity. This will also give way to
understanding the mechanisms allowing the functional ameliora-
tion that takes place after transplantation. That different cell types
in the brain undergo degeneration has prompted the notion that
brain repair consists of several mechanisms facilitating various
types of cells working together with the trophic, neurogenic, vas-
culogenic, and other by-stander effects of the transplanted stem
cells (75). Accordingly, such multi-pronged cellular repair process
necessitates the need to determine the source of the stem cells to
aid in realizing the therapeutic effects and mechanisms of action
associated with cell therapy. Another aspect to consider is the abil-
ity of the cells to be shipped frozen and thawed for transplantation
at the clinic, which is important for neonatal diseases which may
benefit from early intervention. Moreover, using autologous stem
cells can be of an advantage due to their ability to bypass graft
rejection along with its side effects. For example, in a study where
intravenous injection of autologous cord blood was made, the
results showed that they were safe in CP children (76). In parallel,
placental tissue obtained during prenatal chorionic villous sam-
pling or at delivery can be a good source of autologous stem cells
which can be transplanted during the last month of gestation or
the first few months after delivery if neurodegeneration is detected
in the baby (77).
FUNCTIONAL OUTCOMES IN CELL TRANSPLANTATION IN HIE
To assess the safety and efficacy of the treatment group in HIE, spe-
cific behavioral and histological procedures are frequently used.
These assays can determine motor and cognitive amelioration as
well as provide insight to the biochemical processes that are under-
going in the brain (68, 78, 79). However, to value the functional
improvement after cell transplantation in animals, a close esti-
mate of the HIE clinical symptoms needs to be shown in these
preclinical models (80–83). In addition, monitoring the safety
and efficacy of stem cells over time will allow a better assess-
ment of the effects of cell therapy (84). This becomes an obstacle
for neonatal HIE due to the spontaneous amelioration seen in
the development and maturation phases of the neonatal animal
(85) and in pediatric patients (86). More sensitive functional out-
comes may be needed to delineate spontaneous recovery from true
therapeutic benefits of cell therapy; for example, to examine the
grafted cells and host HIE microscopically, specific markers for
the trophic factor effect, immunomodulatory response, neuro-
genesis, vasculogenesis, angiogenesis, and synaptogenesis, as well
as inflammation, tumorigenesis ,or ectopic tissue formation may
be used (87–89). This approach allows a better understanding of
the cells’ mechanism of action and indication of unfavorable side
effects.
MECHANISMS OF ACTION UNDERLYING CELL THERAPY
Two major modes of action are involved in stem cell-mediated
functional recovery in ischemic brain injury: cell replacement
and by-stander effect. Cellular and molecular neurorestorative
mechanisms include neurogenesis, angiogenesis, synaptogenesis,
immunomodulation, and trophic factor secretion (30, 31, 90).
Real-time visualization techniques (i.e., magnetic resonance imag-
ing), originally performed in stroke and extended to HIE models
(91–93), have allowed, recently, the tracking of the transplant,
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as well as the imaging of the host neurorestorative mechanisms
(94–100). The neurorestorative mechanism is characterized by
transplantation of stem cells that serve as biobridge for the ini-
tiation of endogenous repair mechanisms (101). The transplanted
stem cells pave the way between the neurogenic niche and injured
brain site in order to traffic the migration of host neurogenic
cells (101).
OUTSTANDING PRECLINICAL ISSUES NECESSARY FOR
CLINICAL TRIALS OF CELL THERAPY IN HIE
Preclinical trials on stem cells in cerebral palsy have been con-
ducted and have shown significant improvement in animal mod-
els. However, results have been difficult to replicate in humans
since most of the studies have been on acute hypoxic injury mod-
els, which are less similar to human cases compared to chronic
models. So far, clinical trials on children with cerebral palsy (CP)
have suggested that neural progenitor cells (NPC), umbilical cord
mononuclear cells, and mesenchymal stem cells (MSC) trans-
plants are safe, and could improve motor and cognitive functions
(102). Currently, there are three ongoing registered clinical trials
on stem cells and CP on children, and two that have recently been
completed.
Two of these clinical trials are currently being conducted in
the United States, with the aim of testing the safety and efficacy
of autologous cord blood cells. The primary outcomes should be
expected by the year 2015. Although patient recruitment is not
open, China intends to test the efficacy of umbilical cord MSC
versus rehabilitation treatments on children with cerebral palsy. In
Iran, two clinical trials have already been completed. These clinical
trials studied the efficacy of multiple intrathecal bone marrow-
derived CD133 cell transplantation in children with cerebral palsy.
Results are not published yet (103).
It is imperative to set the parameters defining safety and effi-
cacy of stem cell therapy in neonatal HIE clinical trials. In the
United States, the Medical College of Georgia and Duke Univer-
sity are assessing the safety and efficacy of umbilical cord blood
transplants in CP pediatric patients. The long-term efficacy of
intravenous transplantation of autologous cord blood in CP chil-
dren remains to be determined (76, 104). So far, autologous bone
marrow-derived MSCs have also been found to be safe when trans-
planted, but it was only on one CP patient (105). Autologous stem
cell sources have been preferred largely due to their safety pro-
file, but cell types that have already committed to a particular
lineage or niche in the brain also have the potential to be used
as donor cells. In order to implement cell therapy in neonatal
ischemic-injury patients, there should be sufficient evidence of
safety, efficacy, and mechanism of action of the stem cells in ani-
mal models. Moreover, it has been difficult to obtain a projection
of the neurologic outcomes of cell therapy in neonatal hypoxic-
ischemic injury. The current reports on clinical improvement after
cell therapy in children with CP or HIE should not interfere with
the need for sufficient preclinical studies for the advancement of
clinical trials. The guidelines mentioned in the previous sections
on the Baby STEPS may also be implemented to other poten-
tial therapies for neonatal hypoxic-ischemic injury (106–109) and
should be used along with the current pediatric stroke recom-
mendations in research and treatment interventions (110–113).
In the end, while autologous stem cells have shown to be safe and
effective as a possible treatment for HIE, more preclinical studies,
paralleled by carefully designed limited clinical trials should be
conducted before moving into larger studies.
CELL THERAPY AND ADJUNCTIVE TREATMENT WITH
HYPOTHERMIA
The current therapies for HIE attempt to interrupt the pathways
activated by HIE. In neonates with HIE, the results have not been
promising in regards to preventing the neuronal loss (114, 115).
In research models of HIE, it has been shown that hypothermia
reduces the release of glutamate (116), reduces the secondary
energy failure (21, 61, 116–118), normalizes protein synthesis
(119), and reduces the injury by free radicals (115). Small trials
of hypothermia conducted on human neonates (117, 118) showed
promising results, while three large trials showed improvement
in the neurodevelopment in neonates with mild to moderate HIE,
but showed no improvement in neonates with severe HIE (20–22).
There is evidence that hypothermia may exert neuroprotection by
reducing the neurodevelopmental disability at 18 months of age in
newborns with either moderate or severe HIE (120). Neuroprotec-
tive approaches could reduce the initial tissue damage, however,
cell therapy will still be required to repair the already damaged
regions of the brain. This approach can then be implemented on
neonates with moderate to severe HIE.
In normal physiological conditions, the endoplasmic reticulum
(ER) and mitochondria sequester calcium when intracellular levels
increase (121). Calcium enters the cell through voltage-sensitive
calcium channels and agonist-operated calcium channels, which
are activated by glutamate, N -methyl-d-aspartate (NMDA) and
kainate, and quisqualate (K/Q) (121). In the ischemic cascade,
the increase in hydrogen displaces calcium from intracellular pro-
teins and intracellular calcium levels increase eventually leading
to mitochondrial dysfunction (121). In addition, calcium acti-
vates intracellular proteases and depolarization occurs in the cell
membrane, releasing a large number of excitatory neurotrans-
mitters such as glutamate (121). This activates NMDA receptors
persistently, causing intracellular hyperosmolarity in the post-
synaptic cell eventually leading to neuronal death (121). More-
over, the ongoing sodium influx inhibits the normal magnesium
blockade on NMDA receptors (121). Hypothermia significantly
reduces extracellular levels of excitatory neurotransmitters (121).
The release of these neurotransmitters is temperature dependent
and even mild levels of hypothermia exert an inhibitory effect
(121). Hypothermia promotes the survival of neurons through
an interaction on glycine since NMDA receptors require the
presence of glycine to be activated (121). Hypothermia signifi-
cantly decreases brain glycine levels after ischemia, thus decreasing
hyperexcitability by glutamate (121).
Hypothermia exerts neuroprotection in HIE against aberrant
stages of region-specific brain maturation (122), blood–brain bar-
rier (BBB) impairment (123), and apoptosis due to mitochondrial
dysfunction (124). Because hypothermia is most efficacious within
the first 6 h of life for the infant with moderate to severe HIE
(125–127), the patient may benefit even more with the use of a
combinatorial therapies (128, 129). For example, using erythro-
poietin and helium, both which are in clinical trials (130–132),
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should be considered for in combination therapy. The treatment
considerations for hypothermia in addition to combining other
therapies are based on the evolving pathophysiology of neona-
tal brain injury, discussed by Ferriero et al. (133, 134). Using a
combination of therapies may be more beneficial to tackle the acti-
vated cell death pathways; moreover, detecting it early in at-risk
newborns may help prevent or reduce the disabilities following
neonatal brain injury (133, 134).
As discussed above, accumulating experimental data have indi-
cated the mobilization of bone marrow-derived stem cells, such as
MSCs, in brain plasticity and therapy of HIE to the affected area
(135). In the clinic, MSCs can be obtained from umbilical cord
blood, adipose tissue, amniotic fluid/tissue, or menstrual blood
(136). As alluded earlier, autologous MSCs may be the preferred
stem cells to avoid adverse effects associated with graft rejection,
but allogeneic MSCs may also be equally safe and effective because
of their immature immune system, as well as their capacity to
secrete anti-inflammatory factor (136). MSCs are capable of dif-
ferentiation into variety of phenotype cells (130, 137) and have
been demonstrated to exert a therapeutic benefit against brain
injury (125). However, little is known regarding MSC treatment
for HIE, especially in combination with hypothermia.
The observation that seizure onset beyond the first 12 h of
life is not only common in newborns with HIE (138), but also
is associated with severe brain injury (56), advances the notion
of a critical relationship between the onset of neonatal seizure
and initiation of the therapy. Accordingly, any treatment regimen,
including hypothermia, is likely to exert benefit if initiated within
6 h after hypoxic-ischemic injury and continuing over the next
12 h or even beyond (i.e., for 72 h) (138). The mechanism under-
lying hypothermia remains elusive, but may include its capacity to
reduce oxidative stress, energy deficit, and inflammation (139).
Because of the dismal prognosis of infants with HIE, clinical
enthusiasm for a novel treatment is understandable (140). Based
on preclinical studies, accumulating evidence suggests that in order
to treat more effectively neonatal HIE, and many other neurode-
generative diseases, combination therapy can be of great help. As
ischemic brain injuries have two separate cascades of events, one
immediately after injury and one persisting even weeks after, it
is important to use combination therapy which can tackle both
events at different times. We highlight here that hypothermia could
be a great neuroprotective method implemented early in HIE,
while stem cells could have a better neurorestorative approach,
especially during the chronic stage of the disease, which starts days
after (i.e., 72 h after birth).
As mentioned previously, combination therapy may be the best
approach to treat neonatal HIE, especially when a definite ther-
apeutic time frame has not been fully established. The use of
other possible neuroprotective strategies has been studied and is
believed to enhance the therapeutic effects of hypothermia by tar-
geting different therapeutic windows and stages of HIE. Oxygen
free radicals are usually elevated after hypoxic-ischemic injury.
The use of antioxidants like superoxide dismutase, combined
with polyethylene glycol to facilitate infiltration across the blood–
brain barrier, can degrade reactive oxygen species to ameliorate
the negative effects of hypoxia. Nonetheless, neuroprotection in
newborn animals has only been seen when administered prior to
injury. Xanthine oxidase inhibitors, like allopurinol and oxypuri-
nol, have also shown to reduce concentrations of free radicals in
infants when administered early during the recovery phase, while
administration of lazeroids appears to inhibit iron-dependent lipid
peroxidation in immature models of hypoxic-ischemic brain dam-
age (141, 142). Epo appears to have a longer therapeutic window
(24–48 h after delivery) compared to hypothermia. Administra-
tion of Epo leads to a reduction in white matter injury, free radical
production, and glutamate cytotoxicity in neonates after a hypoxic
event by increasing the system XC-expression (130, 142, 143).
System XC exchanges 1 mol of cystine for 1 mol of glutamate lead-
ing to increased cellular viability (143). The therapeutic effects of
hypothermia and IV melatonin in perinatal asphyxia piglets model
have been reported (144). Glutamate antagonists such as MK-801
have been show to reduce brain damage after hypoxic-ischemia in
neonatal animal models (141, 144). The accumulation of calcium
in the cytosol is also characteristic of hypoxic-ischemia. Flunar-
izine, a Ca+ channel blocker, has shown to have a neuroprotective
effects when administered prior to injury in fetus and newborn
animals (141). Magnesium sulfate has also shown to be a potential
treatment to reduce newborn brain injury (in rats) by blocking the
neuronal influx of Ca+within the ion channel, while it could also
reduce the incidence of moderate to severe CP (141,144). However,
the use of Ca+ blockers has been linked to adverse cardiovascular
effects on infants, contraindicating their use. It has been observed
that neuronal loss can be reduced through the administration of
NOS inhibitors in immature rats; however, further studies need
to be conducted in order to prove its effectiveness in other animal
models (141). Neuroprotective effects after the administration of
noble gases like xenon, argon, and helium 2 h post hypoxic injury
in 7-day-old SD rat has been reported. Although helium seems
to be neuroprotective only in mild hypoxic-ischemic injury, argon
and xenon showed neuroprotection in severe hypoxic animal mod-
els by increasing Bcl-2 and Bcl-xL, as well as reduction of infarct
size and long-term neurocognition (144, 145). There are still many
potential neuroprotective strategies to be studied including protec-
tion by neural stem cells and the ependymal lining of the ventricles,
among others, which will similarly require further investigations
for HIE applications.
The use of delta opioid agonists may resemble certain physi-
ological correlation of hibernation, including hypothermia (71),
which may involve direct opioid receptor activation, as well as
non-opioid mechanisms (71, 146, 147). Interestingly, delta opi-
oids may regulate neural stem and progenitor cell proliferation
and differentiation (148), and may even enhance cell-based ther-
apeutics in in vitro and in vivo disease models (149). Our recent
study (150) revealed that moderate hypothermia is efficacious in
an in vitro model of hypoxic-ischemic injury, which was enhanced
by MSC treatment. We also showed that the delta opioid system,
along with other non-opioid neuroprotective processes, primarily
contributes to the observed neuroprotection in HIE. Stem cell ther-
apy using MSCs significantly improved the therapeutic outcome
of moderate hypothermia. Primary rat neurons were exposed
to oxygen-glucose deprivation (OGD) condition, a model of
hypoxic-ischemic injury, then incubated at 25°C (severe hypother-
mia), 34°C (moderate hypothermia), and 37°C (normothermia)
with or without subsequent co-culture with MSCs. Combination
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treatment of moderate hypothermia and MSCs proved to be the
optimal condition for preserving cell survival and mitochon-
drial activity after OGD exposure. Pharmacologic induction of
hypothermia in human embryonic kidney cells (HEK293) via
treatment with delta opioid peptide (DADLE) resembled moder-
ate hypothermia’s attenuation of OGD-mediated cell alterations,
which were much more pronounced in HEK293 cells overexpress-
ing the delta opioid receptor. Further, the addition of DADLE to
34°C hypothermia and stem cell treatment in primary rat neurons
showed synergistic neuroprotective effects against OGD which
were significantly more robust than the dual combination of mod-
erate hypothermia and MSCs, and were significantly reduced, but
not completely abolished, by the opioid receptor antagonist nal-
trexone altogether implicating a ligand–receptor mechanism of
neuroprotection. Investigations into other therapeutic signaling
pathways revealed growth factor upregulation (i.e., GDNF) and
anti-apoptotic function accompanying the observed therapeutic
benefits. These results support combination therapy of hypother-
mia and stem cells for hypoxic-ischemic injury, which may have
direct impact on current clinical trials using stand-alone hypother-
mia or stem cells for treating neonatal hypoxic-ischemic brain
injury.
The use of hypothermia as a treatment strategy is not limited to
neonates. In adults, hypothermia has been regarded as a therapeu-
tic strategy to improve the patient’s survival and reduce neurologic
injury after cardiac arrest (151). Small clinical trials provide evi-
dence of hypothermia as a potential treatment for traumatic brain
injury (TBI) as it significantly reduced rates of death, vegetative
state, and long-term disability (152). Although not regarded as
a treatment strategy for spinal cord injury (SCI), the control of
pressure around the injured spinal cord along with the improved
behavioral outcome in animal studies demonstrates the poten-
tial of systemic hypothermia as a method of treating acute SCI
(153). When used in combination with recombinant tissue plas-
minogen activator, animal data also show a reduction in brain
hemorrhage and blood–brain barrier disruption, indicating the
synergistic potential of hypothermia in stroke (154).
In addition, the use of stem cells as a therapeutic strategy in
adults has obtained much attention due to the substantial ben-
eficial data gathered in animal and clinical studies. For example,
specific disease-relevant neurons can be obtained from induced
pluripotent stem cells including dopaminergic neurons for Parkin-
son’s disease (PD), hippocampal and cholinergic neurons for
Alzheimer’s disease, motor neurons for amyotrophic lateral sclero-
sis, and inhibitory interneurons for schizophrenia (155). Embry-
onic stem cells can be made to also differentiate into dopaminergic
neurons and have been shown to ameliorate the behavioral deficit
in animal models of PD (156). Embryonic neural stem cells are also
considered in demyelinating diseases, such as multiple sclerosis, to
replace glial cells that have been lost (156). In addition, the use of
neural stem cells in Huntington’s disease has been evident (156).
SYNOPSIS
Stem cell therapy has the potential to become a treatment method
for neonatal hypoxic-ischemic brain injury, but it needs to be first
implemented in the clinic on patients with neonatal hypoxic-
ischemic brain injury. This will require further translational
research studies so that stem cell therapy can be fully implemented.
Stem cell therapy can also benefit from the ongoing trials of stem
cell therapy in adult stroke due to the similarities in pathology.
Neonatal hypoxic-ischemic injury, however, has distinct symp-
toms from adult stroke (157–159) that will demand modifications
to the translational approach before it can be applied to the clinic.
Combining both hypothermia and stem cell therapy may further
improve the results of cell therapy in neonatal hypoxic-ischemic
injury. The results from using this combinatorial approach can be
then measured by behavioral and histological assays. In addition,
using biomarkers to monitor the transplanted cells in the patient
over time will contribute to exposing the long-term effects of this
combinatorial therapy.
Currently, the use of stem cells for neonatal hypoxic-ischemic
brain injury is still in its experimental phase. Although clinical
trials are scheduled to be conducted using autologous umbilical
cord blood cells on CP children, there still needs to be a suffi-
cient amount of data demonstrating the safety and efficacy before
transplantation therapy can be used in other neonatal diseases.
It is a priority to obtain standardized experimental models with
quantitative functional endpoints and predictive clinical outcomes
so that translational research can be implemented. In addition, it
is important to address and modify the following for an effec-
tive future use of stem cell therapy: the route of delivery, cell
dose, and timing of transplantation after diagnosis of neonatal
brain injury. It should also be noted that because it is difficult
to detect encephalopathy in premature babies due to the lack
of advanced imaging devices and sufficient studies, initial cell
therapy clinical trials will consist of full term infants. Because
it is agreed that HIE involves several cell death pathways, it is
expected that more laboratory research on combination thera-
pies will be conducted in the future. Specifically, incorporating
clinical stage therapies, such as hypothermia and other neuropro-
tective strategies, with stem cell transplantation therapy will be
of future focus. Moreover, the safety and efficacy of these com-
binatorial strategies for neonatal hypoxic-ischemic brain injury
can be maximized by following pertinent translational research
guidelines [e.g., Ref. (32)].
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